Efficacy and Safety Study of Benralizumab in Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) - ORCHID

Study identifier:D3252C00002

ClinicalTrials.gov identifier:NCT04157335

EudraCT identifier:2021-000267-72

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID)

Medical condition

Nasal polyposis

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

296

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 25 Nov 2019
Estimated Primary Completion Date: 19 Aug 2024
Estimated Study Completion Date: 10 Oct 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria